Cynapsus Therapeutics Inc  

(Public, CVE:CTH)   Watch this stock  
Find more results for CTH
Nov 27 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.38 - 1.51
Open     -
Vol / Avg. 0.00/303,419.00
Mkt cap 98.66M
P/E     -
Div/yield     -
EPS -0.14
Shares 79.56M
Beta 0.81
Inst. own     -

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -45.54% -46.11%
Return on average equity -47.97% -49.53%
Employees 25 -
CDP Score - -


828 Richmond St W
+1-416-7032449 (Phone)
+1-416-7038752 (Fax)


Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a turning ON medication designed to convert a PD patient from the OFF to the ON state while avoiding the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes. Furthermore, the Company has initiated its pivotal Phase three clinical program for APL-130277.